Literature DB >> 3707111

Differential effect of impaired renal function on the kinetics of clavulanic acid and amoxicillin.

F F Horber, F J Frey, C Descoeudres, A T Murray, F C Reubi.   

Abstract

Amoxicillin and clavulanic acid are prescribed as a fixed drug combination. The purpose of the present study was to assess the influence of various degrees of renal insufficiency (glomerular filtration rate [GFR], less than 5 to greater than 75 ml/min per 1.73 m2) on the pharmacokinetics of amoxicillin and clavulanic acid following oral (500 and 125 mg of amoxicillin and clavulanic acid, respectively) and intravenous (1,000 and 200 mg, respectively) dosing. The volume of distribution and the systemic availability were independent of the renal function, while the total body clearance and the renal and the nonrenal clearance of amoxicillin and clavulanic acid decreased with decreasing renal function. The decrease in the total body clearance was more pronounced for amoxicillin than for clavulanic acid. This explains the increase in the ratio of the area under the plasma concentration versus time curve of amoxicillin to that of clavulanic acid with decreasing glomerular filtration rate after oral dosing; for example for a GFR of 75 ml/min, the ratio of amoxicillin to clavulanic acid was 4.9 +/- 1.2; for a GFR of 35 to 75 ml/min, 5.3 +/- 2.4; for a GFR of 10 to 35 ml/min, 11.9 +/- 5.8; for a GFR of 5 to 10 ml/min, 13.4 +/- 9.1; and for patients on hemodialysis, 14.7 +/- 5.3. Dosage recommendations are suggested which prevent undue accumulations of amoxicillin while maintaining adequate concentrations of clavulanic acid.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707111      PMCID: PMC180453          DOI: 10.1128/AAC.29.4.614

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  In vitro study of clavulanic acid in combination with penicillin, amoxycillin, and carbenicillin.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

2.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

Review 3.  Plasmid-mediated beta-lactamases of Gram-negative bacteria: properties and distribution.

Authors:  M Matthew
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

4.  Effect of clavulanic acid and amoxycillin formulation against beta-lactamase producing Gram-negative bacteria in urinary tract infections.

Authors:  F W Goldstein; M D Kitzis; J F Acar
Journal:  J Antimicrob Chemother       Date:  1979-11       Impact factor: 5.790

5.  Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.

Authors:  A P Ball; A M Geddes; P G Davey; I D Farrell; G R Brookes
Journal:  Lancet       Date:  1980-03-22       Impact factor: 79.321

6.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

7.  The inhibition of staphylococcal beta-lactamase by clavulanic acid.

Authors:  C Reading; P Hepburn
Journal:  Biochem J       Date:  1979-04-01       Impact factor: 3.857

8.  Determination of the hepatic elimination capacity (Lm) of galactose by single injection.

Authors:  N Tygstrup
Journal:  Scand J Clin Lab Invest Suppl       Date:  1966

9.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

10.  Kinetics of procainamide and N-acetylprocainamide in renal failure.

Authors:  T P Gibson; A J Atkinson; E Matusik; L D Nelson; W A Briggs
Journal:  Kidney Int       Date:  1977-12       Impact factor: 10.612

View more
  10 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  Sodium thiosulfate pharmacokinetics in hemodialysis patients and healthy volunteers.

Authors:  Stefan Farese; Emilie Stauffer; Robert Kalicki; Tatjana Hildebrandt; Brigitte M Frey; Felix J Frey; Dominik E Uehlinger; Andreas Pasch
Journal:  Clin J Am Soc Nephrol       Date:  2011-05-12       Impact factor: 8.237

3.  High haemodialysis clearance of ornidazole in the presence of a negligible renal clearance.

Authors:  F F Horber; O Maurer; P J Probst; E Heizmann; F J Frey
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Pharmacokinetics of amoxycillin and clavulanic acid in haemodialysis patients following intravenous administration of Augmentin.

Authors:  B E Davies; R Boon; R Horton; F C Reubi; C E Descoeudres
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.

Authors:  I D Watson; M J Stewart; D J Platt
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 7.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

8.  Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and Monte Carlo simulation.

Authors:  Cornelia B Landersdorfer; Martina Kinzig; Jürgen B Bulitta; Friedrich F Hennig; Ulrike Holzgrabe; Fritz Sörgel; Johannes Gusinde
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

9.  Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3.

Authors:  Sînziana Cristea; Elke H J Krekels; Karel Allegaert; Peter De Paepe; Annick de Jaeger; Pieter De Cock; Catherijne A J Knibbe
Journal:  AAPS J       Date:  2021-05-04       Impact factor: 4.009

Review 10.  Drug-Dosing Adjustment in Dogs and Cats with Chronic Kidney Disease.

Authors:  Francesca De Santis; Andrea Boari; Francesco Dondi; Paolo Emidio Crisi
Journal:  Animals (Basel)       Date:  2022-01-21       Impact factor: 2.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.